Mass Spectrometry in Myeloma: Can a Blood Test Reduce Bone Marrow Biopsies? | IMS 2026

Noemi Puig, MD, PhD, of University Hospital of Salamanca discusses the role of mass spectrometry in diagnosing and monitoring myeloma at IMS 2026 in Glasgow. She explains how this test tracks the unique fingerprint of each patient's monoclonal protein and detects remaining disease in about a quarter of patients who look negative on standard tests. Viewers will learn how it may help time and reduce bone marrow biopsies, why it cannot yet replace them, and when it may become widely available.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction
0:31 Why mass spectrometry for myeloma monitoring?
2:40 How it works: the monoclonal protein fingerprint
3:22 What we've learned: more sensitive than conventional tests
4:06 Using mass spec to time bone marrow tests
5:11 Can we get rid of bone marrow aspirations?
5:46 Is mass spectrometry widely available?
6:39 Will bone marrow biopsies still be needed?